CT TAVR Abdomen Study

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-88
SponsorUniversity of Maryland, Baltimore

About this trial

A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.

Eligibility criteria

Qualifiers

scheduled to receive TAVR abdominal CT

Disqualifiers

cannot undergo CT scan

Allergy to intravenous contrast not controlled by steroids or benadryl

GFR<30

Trial design

Treatments tested in this trial

  • Iodinated Contrast Agent (Omnipaque)
  • Dual Energy CT

Treatment groups

164 Participants
are divided into 2 treatment groups